

Murat Akova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5700333/publications.pdf>

Version: 2024-02-01

125
papers

14,349
citations

41344

49
h-index

20358

116
g-index

133
all docs

133
docs citations

133
times ranked

15842
citing authors

#	ARTICLE	IF	CITATIONS
1	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , 2012, 18, 19-37.	6.0	977
2	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
3	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	5.8	843
4	The global threat of antimicrobial resistance: science for intervention. <i>New Microbes and New Infections</i> , 2015, 6, 22-29.	1.6	811
5	Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. <i>Clinical Microbiology and Infection</i> , 2012, 18, 413-431.	6.0	727
6	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. <i>Lancet</i> , The, 2021, 398, 213-222.	13.7	683
7	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1859-1867.	6.0	566
8	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014, 20, 5-26.	6.0	547
9	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. <i>Clinical Microbiology and Infection</i> , 2014, 20, 76-98.	6.0	400
10	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <i>Clinical Microbiology and Infection</i> , 2014, 20, 27-46.	6.0	383
11	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	9.1	367
12	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) <i>Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>		
13	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , 2012, 18, 9-18.	6.0	310
14	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , 2012, 18, 53-67.	6.0	280
15	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by <i>Candida</i> spp.. <i>Clinical Microbiology and Infection</i> , 2012, 18, 38-52.	6.0	264
16	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014, 20, 47-75.	6.0	262
17	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1. <i>Thorax</i> , 2015, 70, 984-989.	5.6	224
18	Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. <i>Journal of Infection</i> , 2014, 68, 321-331.	3.3	223

#	ARTICLE	IF	CITATIONS
19	Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. <i>Clinical Microbiology and Infection</i> , 2010, 16, 102-111.	6.0	216
20	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, i5-i14.	3.0	178
21	Prevalence of mcr-1 in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> recovered from bloodstream infections in China: a multicentre longitudinal study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 400-410.	9.1	177
22	Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. <i>Clinical Microbiology and Infection</i> , 2012, 18, 439-448.	6.0	170
23	Epidemiology of antimicrobial resistance in bloodstream infections. <i>Virulence</i> , 2016, 7, 252-266.	4.4	153
24	Multidrug efflux inhibition in <i>Acinetobacter baumannii</i> : comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine- β -naphthylamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 970-974.	3.0	148
25	Risk factors for target non-attainment during empirical treatment with β -lactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 1340-1351.	8.2	147
26	The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 679-683.	0.9	139
27	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	3.2	137
28	Multidrug-resistant bacteria in solid organ transplant recipients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 49-73.	6.0	136
29	Metallo- β -lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 380-388.	2.5	134
30	Task force on management and prevention of <i>Acinetobacter baumannii</i> infections in the ICU. <i>Intensive Care Medicine</i> , 2015, 41, 2057-2075.	8.2	133
31	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	3.0	129
32	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	3.3	125
33	European expert opinion on the management of invasive candidiasis in adults. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1-12.	6.0	113
34	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.	5.8	108
35	Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 344-348.	3.0	103
36	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018, 44, 189-196.	8.2	101

#	ARTICLE	IF	CITATIONS
37	High prevalence of ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in community-onset bloodstream infections in China. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 273-280.	3.0	93
38	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , 2012, 18, 1-8.	6.0	91
39	Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 851-858.	3.2	91
40	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	3.0	89
41	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.	5.8	87
42	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , 2012, 18, 68-77.	6.0	81
43	Infections in the Elderly Critically-Ill Patients. <i>Frontiers in Medicine</i> , 2019, 6, 118.	2.6	75
44	Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy—EORTC Infectious Diseases Group Trial XV. <i>Journal of Clinical Oncology</i> , 2013, 31, 1149-1156.	1.6	72
45	The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. <i>International Journal of Infectious Diseases</i> , 2008, 12, 71-79.	3.3	71
46	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of Secondary Infections in Febrile, Neutropenic Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2005, 40, 239-245.	5.8	56
47	Sulbactam-containing β -lactamase inhibitor combinations. <i>Clinical Microbiology and Infection</i> , 2008, 14, 185-188.	6.0	55
48	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. <i>Intensive Care Medicine</i> , 2020, 46, 1404-1417.	8.2	54
49	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019, 62, 310-319.	4.0	53
50	Bacterial infection prevention after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 467-470.	2.4	51
51	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.8	49
52	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 423-430.	2.5	48
53	Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. <i>European Radiology</i> , 2021, 31, 1090-1099.	4.5	48
54	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	3.0	46

#	ARTICLE	IF	CITATIONS
55	Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. <i>Infectious Diseases</i> , 2015, 47, 686-693.	2.8	45
56	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	5.8	43
57	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	3.0	41
58	Efficacy of β -Lactam/ β -Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	41
59	Management of febrile neutropenia in the era of bacterial resistance. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 37-43.	1.8	30
60	Developing and evaluating professionalism. <i>Medical Teacher</i> , 2006, 28, 36-39.	1.8	27
61	Leading infectious diseases problems in Turkey. <i>Clinical Microbiology and Infection</i> , 2012, 18, 1056-1067.	6.0	25
62	Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001). <i>Supportive Care in Cancer</i> , 2006, 14, 52-55.	2.2	24
63	Laboratory-acquired brucellosis in Turkey. <i>Journal of Hospital Infection</i> , 2012, 80, 326-330.	2.9	24
64	Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. <i>Mycoses</i> , 2015, 58, 498-505.	4.0	24
65	A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 276.	1.6	24
66	Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. <i>Clinical Microbiology and Infection</i> , 2015, 21, e25-e27.	6.0	23
67	Dual Role of <i>gnaA</i> in Antibiotic Resistance and Virulence in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	23
68	Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 519-525.	2.9	22
69	Epidemiology of carbapenem-resistant <i>Klebsiella pneumoniae</i> colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 466-470.	1.8	22
70	Molecular characterization of NDM-1-producing <i>Acinetobacter pittii</i> isolated from Turkey in 2006. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3437-3438.	3.0	21
71	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. <i>European Journal of Internal Medicine</i> , 2017, 37, 13-18.	2.2	21
72	Low-level laser therapy supported teeth extractions of two patients receiving IV zoledronate. <i>Lasers in Medical Science</i> , 2011, 26, 569-575.	2.1	18

#	ARTICLE	IF	CITATIONS
73	The Role of Colistin in the Era of New \hat{I}^2 -Lactam/ \hat{I}^2 -Lactamase Inhibitor Combinations. <i>Antibiotics</i> , 2022, 11, 277.	3.7	18
74	A novel fungal pathogen under the spotlight - <i>Acremonium</i> spp. associated fungaemia in an immunocompetent host. <i>Mycoses</i> , 2011, 54, 78-80.	4.0	17
75	Extended spectrum \hat{I}^2 -lactamase producing enterobacteriaceae: carbapenem sparing options. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 969-981.	4.4	17
76	Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study. <i>Journal of Infection</i> , 2021, 83, 175-181.	3.3	17
77	Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant <i>Klebsiella</i> spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 841-847.	2.9	17
78	Emerging problem pathogens: A review of resistance patterns over time. <i>International Journal of Infectious Diseases</i> , 2006, 10, S3-S8.	3.3	15
79	Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 411-420.	0.9	14
80	A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant <i>Klebsiella pneumoniae</i> in an OXA-48 endemic setting. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106554.	2.5	13
81	A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, iii25-iii33.	3.0	12
82	Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. <i>International Journal of Pharmaceutics</i> , 2001, 213, 153-161.	5.2	11
83	Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality. <i>Turkish Journal of Haematology</i> , 2016, 33, 311-319.	0.5	11
84	Nosocomial bloodstream infections in a Turkish university hospital: study of Gram-negative bacilli and their sensitivity patterns. <i>International Journal of Antimicrobial Agents</i> , 2001, 17, 477-481.	2.5	10
85	Fungaemia due to rare yeasts in a tertiary care university centre within 18 years. <i>Mycoses</i> , 2020, 63, 488-493.	4.0	10
86	Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 555-560.	3.1	9
87	Bacteremic and non-bacteremic pneumonia caused by <i>Acinetobacter baumannii</i> in ICUs of South China: A Clinical and Microbiological Study. <i>Scientific Reports</i> , 2017, 7, 15279.	3.3	9
88	Immigrants as donors and transplant recipients: specific considerations. <i>Intensive Care Medicine</i> , 2019, 45, 401-403.	8.2	9
89	Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 385-392.	2.9	9
90	PREDICTORS OF SHORT-TERM OUTCOME OF SPONTANEOUS BACTERIAL PERITONITIS IN TURKISH CIRRHOTIC PATIENTS. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 657-660.	2.8	8

#	ARTICLE	IF	CITATIONS
91	ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017002.	1.3	8
92	Clinical efficacy of $\hat{1}^2$ -lactam/ $\hat{1}^2$ -lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum $\hat{1}^2$ -lactamase-producing <i>Enterobacteriaceae</i> in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). BMJ Open, 2017, 7, e013268.	1.9	8
93	Geographical variation in therapy for bloodstream infections due to multidrug-resistant <i>Enterobacteriaceae</i> : a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
94	The Place and the Efficacy of Infectious Disease Consultations in the Hospitals. Infectious Diseases in Clinical Practice, 2012, 20, 131-136.	0.3	7
95	Treatment of invasive infections due to rare or emerging yeasts and moulds. Expert Opinion on Pharmacotherapy, 2006, 7, 1181-1190.	1.8	6
96	An overview on severe infections in Europe. Intensive Care Medicine, 2017, 43, 686-689.	8.2	6
97	Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4). Turkish Journal of Haematology, 2015, 32, 100-117.	0.5	6
98	Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with <i>Pseudomonas aeruginosa</i> Pneumonia. Microorganisms, 2022, 10, 733.	3.6	6
99	Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey. Vaccines, 2022, 10, 1140.	4.4	6
100	Understanding resistance in <i>Pseudomonas</i> . Intensive Care Medicine, 2020, 46, 350-352.	8.2	5
101	GRACE and the development of an education and training curriculum. Clinical Microbiology and Infection, 2012, 18, E308-E313.	6.0	4
102	Impact of antibiotic resistance on outcomes of neutropenic cancer patients with <i>Pseudomonas aeruginosa</i> bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ Open, 2019, 9, e025744.	1.9	4
103	Do antimicrobial stewardship programs improve the quality of care in ICU patients diagnosed with infectious diseases following consultation? Experience in a tertiary care hospital. International Journal of Infectious Diseases, 2022, 115, 201-207.	3.3	4
104	Occupational Risk of Hepatitis B and C Infections in Urologists. Urologia Internationalis, 1998, 61, 206-209.	1.3	3
105	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.8	3
106	Expect the unexpected: fungemia caused by uncommon <i>Candida</i> species in a Turkish University Hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1539-1545.	2.9	3
107	COVID-19 Vaccination in The Wake of a Fourth Wave of the Pandemic: An Evidence-Based Strategy is Desperately Needed. Infectious Diseases and Clinical Microbiology, 2021, 3, 52-54.	0.3	3
108	CoronaVac efficacy data from Turkey â€œ Authors' reply. Lancet, The, 2021, 398, 1874.	13.7	3

#	ARTICLE	IF	CITATIONS
109	COVID-19 vaccine booster strategy: striving for best practice. <i>The Lancet Global Health</i> , 2022, 10, e774-e775.	6.3	3
110	Reply to Rhodes et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 907-908.	5.8	2
111	The features of infectious diseases departments and anti-infective practices in France and Turkey: a cross-sectional study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 1591-1599.	2.9	2
112	Neuroinvasive Listeriosis. <i>Neurologist</i> , 2018, 23, 86-91.	0.7	2
113	Gram-Negative Infections. <i>Hematologic Malignancies</i> , 2021, , 161-179.	0.2	2
114	Pulmonary nocardiosis caused by <i>Nocardia abscessus</i> mimicking pulmonary thromboembolism in a patient with atypical anti-glomerular basement membrane glomerulonephritis. <i>Tuberkuloz Ve Toraks</i> , 2021, 69, 237-241.	0.4	1
115	The risk of pneumococcal diseases in lung diseases and the importance of adult vaccination. <i>Tuberkuloz Ve Toraks</i> , 2014, 62, 154-159.	0.4	1
116	Vorikonazol Terapötik Etki Düzeyi: Bir Üniversite Hastanesi Deneyimi. <i>Flora: the Journal of Infectious Diseases and Clinical Microbiology = Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi</i> , 2022, 27, 183-188.	0.1	1
117	Comparative In Vitro Activity of Sparfloxacin against Gram-Positive Cocci. <i>Drugs</i> , 1993, 45, 199-200.	10.9	0
118	Antimicrobial Stewardship in Hematology Patients. , 2017, , 205-217.		0
119	1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI). <i>Open Forum Infectious Diseases</i> , 2018, 5, S434-S435.	0.9	0
120	Factors associated with severe lung disease in an adult population with cystic fibrosis: a single-center experience. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 945-952.	0.9	0
121	Microbiological Background. , 2015, , 63-87.		0
122	End of Year, Editorial 2021. <i>Infectious Diseases and Clinical Microbiology</i> , 2021, 3, 109-109.	0.3	0
123	Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-3.	1.8	0
124	Factors Associated with Gram-Negative Bacteremia and Mortality in Neutropenic Patients with Hematologic Malignancies in a High-Resistance Setting. <i>Infectious Diseases and Clinical Microbiology</i> , 2022, 4, 87-98.	0.3	0
125	A Case of Crimean-Congo Haemorrhagic Fever (CCHF) Mimicking the COVID-19 Disease. <i>Acta Medica</i> , 0, , .	0.2	0